Otsuka Sibeprenlimab Shows Significant Proteinuria Reduction
June 6, 2025
In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when